Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
Raltegravir
Merck Sharp & Dohme B.V.
J05AJ01
raltegravir
Antivirals for systemic use
HIV Infections
Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.
Revision: 42
Authorised
2007-12-19
114 PARTICULARS TO APPEAR ON T HE IMMEDIAT E PACKAGIN G ISENTRESS 100 MG – BOTTLE LABELING 1. NAME OF THE MEDICINAL PRODUCT ISENTRESS 100 mg chewable tablets raltegravir 2. STATEMENT OF ACTIVE SUBSTANCE(S ) Each tablet contains 100 mg of raltegravir (as potassium). 3. LIST OF EXCI PIENTS Contains fructose, E 420, sucrose, and E 951. See leaflet for further information. 4. PHARMACEUTICAL FORM AND CONTENTS 60 chewable tablets 5. METHOD AN D ROUTES OF ADMINIS TRATION Read th e package leafle t before use. Oral use 6. SP ECIAL WARNING TH AT THE MEDICINA L PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY Do not switch with othe r strengths or f ormulations of Isentress withou t first talking with your doctor, pharmacist o r nurse. 8. EXPIRY DATE EXP 9. SPECIAL STORAGE CONDITIONS 115 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUC TS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL P RODUCTS, IF AP PROPRIATE 11. N AME AND ADDRESS OF THE MARKETIN G AUTHORISATION HOLDER MSD 12. MARKETING AUTHORISATION NUMBER(S) EU/1/07/436/004 13. BATCH NUMBER Lot 14. GENERAL CLASSIFICATION FOR SUPPLY 15. INSTRUCTIONS ON USE 16. INFORMATION IN BRAILLE 17. UNIQUE IDENTIFIER – 2D BARCODE 18. UNIQUE I DENTIFIER - HUM AN READABLE DATA 116 PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR THE 25 MG CHEWABLE TABLETS 1. NAME OF THE MEDICIN AL PRODUCT ISENTRESS 25 mg chewable tablets raltegravir 2. STA TEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 25 mg of ra ltegravir (as potassium). 3. LIST OF EXCIPIENTS Contains fructose, sorbitol , sucrose and aspartame. See leafle t for further informati on. 4. PH ARMACEU TICAL FOR M AND CONTENTS 60 chewable tablets 5. METHOD AND ROUTES OF ADMINISTRA TION Re ad the package leaflet before use. Oral use 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT A N D REACH OF CHILDREN Keep out of the sight and rea ch of children. 7. OTHER SPE CIAL WARN ING(S), IF Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF T HE MEDICINAL PR ODUCT ISENTRESS 400 mg film- coated tablets 2. QUALITATIVE AND QUA NTITATIVE COMPOSITION Each film-coated tablet contains 400 mg of ralteg ravir (as potassium ). Excipient(s) with known effect Each tablet contains 26.06 mg lactose (as monohydrate). For the full lis t of excipients, see section 6.1. 3. PHARMACE UTI CAL FORM Film-coated tablet. Pink, oval tabl et, marked with "227" on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ISENTRESS is indicated in combination with other anti-ret roviral med icinal products for the treatment of h uman immu nodeficiency virus (HIV-1) infection (see sections 4.2, 4.4, 5.1 and 5.2). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Therapy should be initiated by a physician experienced in the ma nagement of HIV infection. Posology ISENTRESS should be used i n combination with other active anti- retroviral thera pies (ARTs) (see sections 4.4 and 5.1). Adults The recommended dosage is 400 mg (one tablet) twice daily. Paediatric population The recommended dosage for paediat ric patients of at least 25 kg body we ight is 400 mg (one tablet) twice da ily. If unable to swallow a table t, consider the chewable tablet. Additional formul ations and strengths available : ISENTRESS is also available in a chewabl e tablet formulation and in granules for oral suspension formulation Refer to the chewable tablet an d granules for or al suspension Sm PCs for additional dosing information. The safety a nd efficacy of raltegravir in preterm (<37 weeks of gestation) and low b irth weight (<2,000 g) n ewborns have not been established. No da ta are available in this population and no dosing recommendations can be made. The maximum dose of the chewable tablet is 300 mg twice daily. Because the formulations have different pharmacok inetic profiles neither the chewable tablets nor the granules for oral suspension should be substitu ted for the 40 0 mg tablet or 600 mg tablet (see section 5.2). The ch ewable tablets 3 Przeczytaj cały dokument